A phenylacetate derivative, SCK6, inhibits cell proliferation via G1 cell cycle arrest and apoptosis

European Journal of Pharmacology

Volumn 467, Issue 1-3, 2003, Pages 31-39

  Chan, Hsu Chin ^a   Kuo, Sheng Chu ^a   Huang, Li Jiau ^a   Liu, Chung Hsien ^b   Hsu, Shih Lan ^c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Caspase; Cell cycle; Phenylacetate derivative

Indexed keywords

2 (2 FLUOROPHENYL) N ISOPROPYLACETAMIDE; 2 (2 FLUOROPHENYL) N METHYLACETAMIDE; 2 (2 FLUOROPHENYL) N PROPYLACETAMIDE; 2 (2 FLUOROPHENYL)ACETAMIDE; CASPASE 9; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; DNA FRAGMENT; N BUTYL 2 (2 FLUOROPHENYL)ACETAMIDE; N ETHYL 2 (2 FLUOROPHENYL)ACETAMIDE; PHENYLACETIC ACID DERIVATIVE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; SCK 1; SCK 2; SCK 3; SCK 4; SCK 5; SCK 6; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG CARCINOMA; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; UPREGULATION;

EID: 0037466464     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01596-6     Document Type: Article

References (40)

1. Agami R., Bernards R. Convergence of mitogenic and DNA damage signaling in the G1 phase of the cell cycle. Cancer Lett. 177:2002;111-118.
2. Baldin V., Lukas J., Marcote M.J., Pagano M., Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7:1993;812-821.
3. Baliga B.C., Kumar S. Role of Bcl-2 family of proteins in malignancy. Hematol. Oncol. 20:2002;63-74.
4. Bartkova J., Lukas J., Bartek J. Aberrations of the G1- and G1/S-regulating genes in human cancer. Prog. Cell Cycle Res. 3:1997;211-220.
5. Brugarolas J., Chandrasekaran C., Gordon J.I., Beach D., Jacks T., Hannon G.J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377:1995;552-557.
6. Brusilow S.W., Danney M., Waber L.J., Batshaw M., Burton B., Levitsky L., Roth K., McKeethren C., Ward J. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N. Engl. J. Med. 310:1984;1630-1634.
7. Cinatl J., Cinatl J., Mainke M., Weissflog A., Rabenau H., Kornhuber B., Doerr H.W. In vitro differentiation of human neuroblastoma cells induced by sodium phenylacetate. Cancer Lett. 70:1993;15-24.
8. Cinatl J., Cinatl J., Herneiz P., Rabenau H., Hovak M., Benda R., Gumbel H.O., Kornhuber B., Doerr H.W. Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate. Cancer Lett. 78:1994;41-48.
9. Cosentini E., Haberl I., Pertschy P., Teleky B., Mallinger R., Baumgartner G., Wenzl E., Hamilton G. The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification. Int. J. Oncol. 19:2001;1069-1074.
10. Dubrez L., Goldwasser F., Genne P., Pommier Y., Solary E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia. 9:1995;1013-1024.
11. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Ann. Rev. Biochem. 68:1999;383-424.
12. Ferrandina G., Melichar B., Loercher A., Verschraegen C.F., Kudelka A.P., Edwards C.L., Scambia G., Kavanagh J.J., Abbruzzese J.L., Freedman R.S. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res. 57:1997;4309-4315.
13. Froesch B.A., Aime-Sempe C., Leber B., Andrews D., Reed J.C. Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain. J. Biol. Chem. 274:1999;6469-6475.
14. Gore S.D., Samid D., Weng L.J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res. 3:1997;1755-1762.
15. Gorospe M., Shack S., Guyton K.Z., Samid D., Holbrook N.J. Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ. 7:1996;1609-1615.
16. Hudgins W.R., Shack S., Myers C.E., Samid D. Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. Biochem. Pharmacol. 50:1995;1273-1279.
17. Hunter T. Braking the cycle. Cell. 75:1993;839-841.
18. Kotas M., Willner J., Flentje M. Sequential chemo-radiotherapy in non-small cell lung cancer. Lung Cancer. 33(Suppl. 1):2001;S61-S64.
19. Miller A.C., Whittaker T., Thibault A., Samid D. Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate. Int. J. Radiat. Biol. 72:1997;211-218.
20. Nieves-Neira W., Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int. J. Cancer. 82:1999;396-404.
21. Onishi T., Yamakawa K., Franco O.E., Suzuki R., Kawamura J. p27Kip1 is the key mediator of phenylacetate induced cell cycle arrest in human prostate cancer cells. Anticancer Res. 20:2000;3075-3081.
22. Reed J.C. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin. Hematol. 34:1997;9-19.
23. Reed J.C., Miyashita T., Takayama S., Wang H.G., Sato T., Krajewski S., Aime-Sempe C., Bodrug S., Kitada S., Hanada M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell. Biochem. 60:1996;23-32.
24. Samid D., Shack S., Sherman L.T. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res. 52:1992;1988-1992.
25. Samid D., Yeh A., Prasanna P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood. 80:1992;1576-1581.
26. Samid D., Shack S., Myers C.E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest. 91:1993;2288-2295.
27. Samid D., Ram Z., Hudgins W.R., Shack S., Liu L., Walbridge S., Oldfield E.H., Myers C.E. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res. 54:1994;891-895.
28. Sandler M., Ruthven C.R., Goodwin B.L., Lees A., Stern G.M. Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentration values. J. Neurol. Neurosurg. Psychiatry. 45:1982;366-368.
29. Semik M., Schmid C., Trosch F., Broermann P., Scheld H.H. Lung cancer surgery-preoperative risk assessment and patient selection. Lung Cancer. 33(Suppl. 1):2001;S9-S15.
30. Sherr C.J. Mammalian G1 cyclins. Cell. 73:1993;1059-1065.
31. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
32. Sidell N., Wada R., Han G., Chang B., Shack S., Moore T., Samid D. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int. J. Cancer. 60:1995;507-514.
33. Simell O., Sipila I., Rajantie J., Valle D.L., Brusilow S.W. Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. Pediatr. Res. 20:1986;1117-1121.
34. Thibault A., Cooper M.R., Figg W.D., Venzon D.J., Sartor A.O., Tompkins A.C., Weinberger M.S., Headlee D.J., McCall N.A., Samid D. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. 54:1994;1690-1694.
35. Thibault A., Samid D., Cooper M.R., Figg W.D., Tompkins A.C., Patronas N., Headlee D.J., Kohler D.R., Venzon D.J., Myers C.E. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer. 75:1995;2932-2938.
36. Tsai L.H., Lees E., Faha B., Harlow E., Riabowol K. The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene. 8:1993;1593-1602.
37. Uehara T., Kikuchi Y., Nomura Y. Caspase activation accompanying cytochrome c release from mitochondria is possibly involved in nitric oxide-induced neuronal apoptosis in SH-SY5Y cells. J. Neurochem. 72:1999;196-205.
38. Vaux D.L., Korsmeyer S.J. Cell death in development. Cell. 96:1999;245-254.
39. Wang J.L., Liu D., Zhang Z.J., Shan S., Han X., Srinivasula S.M., Croce C.M., Alnemri E.S., Huang Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. U. S. A. 97:2000;7124-7129.
40. Wu L.R. Application of 3-dimensional conformal therapy for non-small cell lung cancer. Clin. Med. (R.O.C.). 41:1998;194-196.